PharmaFluidics appoints Fasha Mahjoor as independent director

 

Board reinforced to bolster further international development for its micro-Chip chromatography products

PharmaFluidics NV, an innovative player in the field of analytical chromatography products with the unique high-resolution μPACTM micro-Chip column, announced the appointment of Fasha Mahjoor as an independent director with effect as of September 6, 2017.


Fasha Mahjoor is the founder of Phenomenex, a global leader in separation sciences and chromatography. Under his leadership and over a period of more than 30 years he built Phenomenex into a global market-leading position, with 780 employees, subsidiary companies in 16 countries, and a network of 60 international partners. In 2016, Fasha Mahjoor elected to sell his company to Danaher Corporation and stayed on as President of Phenomenex until July 2017 to ensure a smooth transition.

For his leadership in the progress of science, Fasha was named to The Analytical Scientist Power List 2013, recognizing the top influencers in the field of analytical sciences.


Currently, Fasha serves as chairman of Farrona LLC, a holdings company made up of Neoteryx LLC, LYKON GMBH, LYKON LLC, and other business ventures into health and wellness industries. Fasha is a noted philanthropist - he received an Ellis Island Medal of Honor in May 2013, from The National Ethic Coalition of Organizations (NECO), for his dedication to humanity. Fasha sits on the board of directors for the American Red Cross (Los Angeles) and The Outward Bound Trust, UK.

Katleen Verleysen, Chair of PharmaFluidics, commented:

“We are excited to welcome Fasha Mahjoor to our board of directors, his association endorsing the value of PharmaFluidics and its technology. Mr. Mahjoor has demonstrated true leadership throughout his career realizing impressive commercial and business successes, and we expect him to make key contributions to the further international development of PharmaFluidics.”


Fasha Mahjoor concluded:

“I am truly delighted to be part of this most innovative company and I expect PharmaFluidics’ technology platform to have a transformative impact in the field of analytical sciences and the business of chromatography”

Note

PharmaFluidics develops and commercializes its unique μPACTM range of micro-chip based chromatography columns for use in biomarker, diagnostics and drug research & development applications in the global biotech and pharma industries. The unprecedented, game-changing separation performance of PharmaFluidics’ μPACTM chromatography columns allows to identify substantially more compounds in complex biological samples, such as biopsies, proteome digests, culture media or bio-pharmaceutical actives.


The key expertise and IP estate of PharmaFluidics are the design, lithographic production, and surface treatment of silicon wafers for use as separation devices in liquid chromatography. PharmaFluidics collaborates with an extensive network of centers of excellence and pioneer users to develop an increasing range of applications.


The μPACTM was brought to market successfully last June.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?